PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currentlycompleting a Phase 1 study in patients with MND/ALS. Top-line results are expected to be announced in Q1CY2024. PAA anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with theUS Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-CellLymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase1 oncology clinical study of monepantel in humans and pilot studies in canine cancer
Going by theiir timeline, nothing happening for awhile!
PAA’s lead MPL program is for the treatment of MND/ALS, a rare,...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.015(7.32%) |
Mkt cap ! $87.1M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 21.0¢ | $134.7K | 629.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24563 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 64222 | 3 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.5¢ |
Change
0.015 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 21.0¢ | 22.0¢ | 21.0¢ | 340156 | ||
| Last updated 15.57pm 07/06/2024 ? | |||||
| PAA (ASX) Chart |